LK Chem is a small- to mid-cap company with a market cap of about ₩132.6 billion that makes and sells chemical materials, and because its revenue and profit move relatively sharply with a single large supply contract or a quarter's results, it is easier to understand by watching how far its recent contract and quarterly results feed through to actual revenue. In May 2026 it signed a single sales and supply contract worth ₩21.2 billion (105.1% of last year's revenue), and it confirmed an earnings improvement with 2025 annual results (revenue ₩20.2 billion, operating profit ₩4.6 billion, net profit ₩4.4 billion) and Q1 2026 results (revenue ₩6.1 billion, operating profit ₩1.1 billion, net profit ₩1.3 billion) in May. The point worth watching lately is that a thick 22.7% operating margin, a new contract exceeding last year's revenue, and a P/E of about 10x on this year's expected profit are strengths; against that, as a small- to mid-cap the outcome hinges heavily on a single contract or a quarter's results, and part of the Q1 growth rate carries a base effect, so it needs checking whether the profit improvement continues in the remaining quarters.

At-a-glance assessment financial health · growth · profitability · valuation

Financial healthStable
  • Debt ratio, current ratio and interest burden all look healthy.
GrowthDeclining
  • Revenue fell 19.4% year over year (3-year trend: mixed).
  • Most recent quarter (Q1 2026) revenue was 79.6% higher than a year earlier.
ProfitabilityModerate
  • ROE is 7.3% (controlling-interest basis). It is above the sector average.
  • Operating margin is 22.7%.
ValuationOvervalued
  • The P/E sits above the sector median, reflecting elevated expectations.

Ownership & governance As of 2025-12-31

Largest shareholder Lee Chang-yeop 56.63% (individual)

Controlling bloc incl. related parties 57.11%

With the controlling bloc holding 57%, control is very secure but the free float is thin.

🔎 In-depth analysis

🏢Business
  • LK Chem is a company that makes and sells chemical materials.
  • As a small- to mid-cap with a market cap of about ₩132.6 billion, its revenue and profit move relatively sharply with a single large supply contract or a quarter's results.
  • So alongside the big picture of the business itself, watching how far its recent contract and quarterly results feed through to actual revenue makes the company easier to understand.
📈Price & chart
  • The latest close is ₩18,700 and the market cap is ₩119.5 billion.
  • The price sits below its 20-day line (₩24,089) and below its 60-day line (₩29,809).
  • Trading beneath both its short- and medium-term moving averages, the trend is on the soft side.
  • RSI (a supplementary gauge that weighs upward against downward force over the past 14 days on a 0-100 scale) is 31.0, a neutral level.
  • The one-month change is -29.2%, the three-month change is -39.2%, and the position relative to the 52-week high is -63.5%.
  • Relative strength versus the KOSDAQ is 60 (on a 1-99 scale, converting the past year's return against the index with more weight on recent periods; higher means stronger than the market).
  • That places it in roughly the top 40% of all stocks by strength.
  • Over the past three months it has lagged the index by 20.7%.
  • Chart reading is best done alongside volume and the dates of disclosures.
📊Key metrics
  • On a 2025 annual basis, revenue is ₩20.2 billion, operating profit ₩4.6 billion and net profit ₩4.4 billion.
  • The operating margin of 22.7% is a thick margin for a chemicals company, and the ROE (how much the company earns on its equity in a year) of 7.3% is above the sector average.
  • Financially, a debt ratio of 111.0%, a current ratio of 1,194% and interest coverage of 10.6x make it solid on short-term funding and debt burden.
  • The P/E (how many times a year's earnings the share price is) is 30.5x on last year's confirmed earnings and the P/B (how many times book value the share price is) is 2.01x, which can look high on the numbers alone.
  • However, this company is at an inflection where profit jumps sharply this year, so the P/E on this year's expected profit shows the company's real value better than the P/E computed on last year's results.
  • The P/E on this year's expected profit comes down to about 9.95x, with an expected P/B of 2.01x, and given that peers' P/E is generally in the 6-12x range, it is hard to call this an expensive spot.
🚀Growth
  • Over several years, revenue went ₩15.3 billion in 2023 to ₩25.0 billion in 2024 to ₩20.2 billion in 2025, rising sharply in 2024 before catching its breath in 2025.
  • Profit followed similarly, peaking in 2024 and then declining in 2025.
  • But in the latest quarter, Q1 2026, the flow clearly turned.
  • Revenue of ₩6.1 billion (+79.6% versus the same period a year earlier), operating profit of ₩1.1 billion (+130.7%) and net profit of ₩1.3 billion (+207.4%) all jumped sharply together.
  • Not only did volume grow; profit grew faster, reading as a sign of better unit pricing or product mix.
  • Add the ₩21.2 billion supply contract signed in May 2026 (larger than all of last year's revenue), and visibility to underpin this year's revenue emerged too.
  • This year's estimates reflecting these Q1 results and the new contract come to about ₩36.2 billion in revenue, ₩10.5 billion in operating profit and ₩13.3 billion in net profit, a step up from last year.
  • That said, the steep Q1 growth rate partly includes a base effect from a low year-earlier quarter, so whether this pace continues in the remaining quarters is something to verify through quarterly results.
📰Recent news & filings
  • On May 14, 2026 it signed a single sales and supply contract (contract value ₩21.2 billion, 105.1% of last year's full-year revenue).
  • Being larger than last year's revenue, it raises this year's revenue visibility, but the contract term and whether this transaction is a one-off or recurring are the key to the medium-term reading.
  • On February 9, 2026 it confirmed annual results (revenue ₩20.2 billion, operating profit ₩4.6 billion, net profit ₩4.4 billion), and on May 15 its quarterly report disclosed Q1 2026 results (revenue ₩6.1 billion, operating profit ₩1.1 billion, net profit ₩1.3 billion), confirming the profit improvement.
  • It helps to check whether the flow of disclosures points in the same direction as the annual trend and whether any one-off factors are mixed in.
🧭Bottom line
  • The strengths are clear.
  • With a 22.7% operating margin, the margin is thick and the financials are solid; in Q1 revenue and profit jumped sharply together, a signal of a profit inflection, and a new supply contract exceeding last year's revenue underpins this year's results.
  • The P/E of 30x computed on last year's profit looks high, but a P/E of about 10x on this year's expected profit is in line with chemicals peers, so if results come through as planned the price is not an expensive spot.
  • That the shares have fallen nearly 60% from their high, diverging from results and price, is also worth noting.
  • On the cautionary side, as a small- to mid-cap the outcome hinges heavily on a single contract or a quarter's results, and the Q1 growth rate partly carries a base effect.
  • In short, if the profit improvement confirmed in Q1 continues in the remaining quarters and the new contract is well recognized as actual revenue, this year's expected profit gains support; conversely, if the contract proves one-off or quarterly results turn down again, that premise weakens.

🔎 Valuation vs peers Overvalued

Chemicals-sector names close in market cap.

PeerP/EP/BROE
Hankook Cosmetics Manufacturing6.31x1.65x26.15%
Clio14.87x0.83x5.58%
Kyung Nong9.52x0.67x7.08%

We looked first at public-data comparables close in market cap within chemicals. The current P/E (how many times a year's earnings the share price is) is 27.46x and the P/B (how many times book value the share price is) is 2.01x. That said, for lower-market-cap names, earnings swings and funding disclosures carry a large effect, so we did not draw firm conclusions from last year's confirmed-results metrics alone. The forecast box is based on DART seasonality approximations.

Earnings outlook company-stated · verified

TypePeriodRevenueOperating profitNet profit
This year2026₩36.2 billion₩10.5 billion₩13.3 billion
Next quarterQ2 2026₩10.3 billion₩4.0 billion₩3.2 billion
₩18,700 +3.95%
Market cap $79.2M

Price history Close · MA20 · MA60

Close MA20MA60

The latest close is ₩18,700 and the market capitalization is ₩119.5 billion. The price sits below its 20-day moving average (₩24,089) and below its 60-day moving average (₩29,809). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 31.0, a neutral level. The one-month change is -29.2%, the three-month change is -39.2%, and the position relative to the 52-week high is -63.5%. Relative strength versus the KOSDAQ is 60 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 60% of all stocks. Over the past three months it lagged the index by 20.7%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.

Relative performance stock vs index · start = 100

60Relative strength vs KOSDAQ1–99 · last 12 months’ return vs the index, recency-weighted · higher = stronger than the marketTop 40% strength

Excess return vs index · 3M -20.66% / 6M -31.36% / 12M -6.81%

StockKOSDAQ

Key metrics vs sector median

Valuation

P/E (trailing)27.46x
P/B2.01x
P/S5.94x
EPS₩681
BPS (book value/share)₩9,323
Dividend yield
DPS

The P/E of 27.46x is above the sector median (14.79x). The P/B of 2.01x is above the sector median (0.97x). That said, this P/E is based on last year's (trailing) results. With recent quarterly earnings up sharply, the trailing P/E can look higher than it really is, so a precise read is best done on this year's expected (forward) earnings.

Enterprise value (EV)

Net debt-$8.3M
EV (enterprise value)$81.5M
EV/EBIT26.90x
EV/Sales6.09x
FCF (free cash flow)-$3.6M
FCF yield-3.97%

EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.

Intrinsic value (DCF estimate)

Bear case₩6,680
Base case₩9,660
Bull case₩15,700

DCF (discounted cash flow) estimate — discount rate 9.8%, initial growth 4.0%→terminal 2.0%, 10-yr forecast, earnings-based. A reference range that shifts materially with assumptions.

Profitability & financials

ROE7.31%
Operating margin22.65%
Net margin21.57%
Debt ratio110.97%
Payout ratio

Return on equity (ROE) is 7.3%, above the sector average (4.0%). The operating margin is 22.7%. The debt ratio is 111.0%, so the financial structure is moderate.

Growth FY2025 · annual report (consolidated)

Item202320242025YoY
Revenue$10.1M$16.6M$13.4M-19.42% ↓ slower
Operating profit$3.7M$6.7M$3.0M-54.91% ↓ slower
Net profit$2.2M$4.5M$2.9M-36.45% ↓ slower
5-year20212022202320242025
Revenue$10.1M$16.6M$13.4M
Operating profit$3.7M$6.7M$3.0M
Net profit$2.2M$4.5M$2.9M
Revenue CAGR2-yr avg 15.01%

Revenue fell 19.4% year over year (2023 ₩15.3 billion → 2024 ₩25.0 billion → 2025 ₩20.2 billion), and the three-year trend is 'mixed'. The rate of decline widened from the prior year. Operating profit fell 54.9% year over year. The decline widened. Over the 3 years on record, revenue compound annual growth (CAGR) is 15.0%. The two-year revenue CAGR is 15.0%. In the most recent quarter (Q1 2026), revenue was 79.6% higher than the same period a year earlier.

Latest quarterly results Q1 2026 · vs year-ago

Revenue$4.0M
Revenue YoY+79.60%
Operating profit$733,442
Op. profit YoY+130.70%
Net profit$883,485
Net profit YoY+207.40%

Technical indicators

RSI (14)31.0
MA20₩24,089
MA60₩29,809
1-month-29.17%
3-month-39.19%
vs 52-wk high-63.55%

What stands out

  • The balance sheet is stable in terms of debt and liquidity.

Points to watch

  • Revenue fell 19.4% year over year (3-year trend: mixed).
  • The price is high versus peers, so expectations already appear priced in.

Recent news & events searched · sourced

Figure cross-check computed ↔ external

MetricComputedExternalStatusSource
Closing price₩18,700₩18,700Confirmedlink
Latest quarterly resultsrevenue ₩6.1 billion, operating profit ₩1.1 billionrevenue ₩6.1 billion, operating profit ₩1.1 billionConfirmedlink
Annual resultsrevenue ₩20.2 billion, operating profit ₩4.6 billionrevenue ₩20.2 billion, operating profit ₩4.6 billionConfirmedlink
Contract disclosure source textㆍapprox. : approx. ₩21.2 billion · revenue 105.1%ㆍapprox. : approx. ₩21.2 billion · revenue 105.1%Confirmedlink
Earnings disclosure source textrevenue30%: revenue ₩20.2 billion · operating profit ₩4.6 billion · net profit ₩4.4 billionrevenue30%: revenue ₩20.2 billion · operating profit ₩4.6 billion · net profit ₩4.4 billionConfirmedlink
Earnings disclosure source text(2026.03): 2026 1 revenue ₩6.1 billion · operating profit ₩1.1 billion · net profit ₩1.3 billion(2026.03): 2026 1 revenue ₩6.1 billion · operating profit ₩1.1 billion · net profit ₩1.3 billionConfirmedlink
Forecast box basisDARTDARTConfirmedlink

Recent filings

📖 Plain-language glossary — expand if you are new to this
P/E
How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
P/B
Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
P/S
Price relative to a year's revenue — useful for growth companies with thin earnings.
Net debt / EV
Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
EV/EBIT · EV/EBITDA · EV/Sales
Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
FCF / FCF yield
Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
Intrinsic value (DCF)
Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
ROE
How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
EPS / BPS
Earnings per share / net assets (book value) per share.
Operating / net margin
Profit left from the core business / final profit after tax and interest, per unit of revenue.
Debt ratio
Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
Current ratio
Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
Interest coverage
How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
Dividend yield / payout ratio
The year's dividend as a % of today's price / the share of earnings paid out as dividends.
Revenue CAGR
Multi-year growth expressed as a single yearly average (compound annual growth rate).
RSI (short-term signal)
Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
MA20 / MA60 (moving averages)
The 20- and 60-day average price. Price above them signals a firmer short-term trend.
vs 52-week high
How far below the past year's peak the price sits now (%).

All figures are for reference only; how they read varies by sector and over time.

Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.

Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.